Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations

20161,263 citationsJournal Articlegreen Open Access

Authors

Daniel Sanghoon Shin · University of California, Los Angeles

Jesse M. Zaretsky · University of California, Los Angeles

Helena Escuin-Ordinas · University of California, Los Angeles

Ángel García-Díaz · University of California, Los Angeles

Siwen Hu‐Lieskovan · University of California, Los Angeles

Anusha Kalbasi · University of California, Los Angeles

Catherine S. Grasso

Abstract

A key functional result from somatic JAK1/2 mutations in a cancer cell is the inability to respond to interferon gamma by expressing PD-L1 and many other interferon-stimulated genes. These mutations result in a genetic mechanism for the absence of reactive PD-L1 expression, and patients harboring such tumors would be unlikely to respond to PD-1 blockade therapy. Cancer Discov; 7(2); 188-201. ©2016 AACR.See related commentary by Marabelle et al., p. 128This article is highlighted in the In This Issue feature, p. 115.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Genetic factors in colorectal cancer Colorectal Cancer Treatments and Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer Discovery

Volume 7, Issue 2, pp. 188-201

DOI: 10.1158/2159-8290.cd-16-1223

Field-Weighted Citation Impact: 55.32